Prof Hope Rugo speaks to ecancer at BGICC 2019 in Cairo about neoadjuvant hormone therapy as a way to treat luminal breast cancer.

She discusses some of the key outcomes from the session including some early biological markers of endocrine sensitivity, one being a fall in Ki-67, that tends to show more positive outcomes.

Prof Rugo hopes to see more widespread use of the PEPI score in order to look at endocrine sensitivity when choosing therapeutic options.